Study #2024-0178
Phase I study of Q702 with azacitidine and venetoclax for relapsed or refractory acute myeloid leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Azacitidine, Venetoclax, Q702
Description
To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Abhishek Maiti
Department:
Leukemia
For general questions about clinical trials:
1-833-922-0089
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.